期刊文献+

含4-乙基吡啶的抗转移NAMI、NAMI-A衍生物的水解动力学及稳定性研究

Hydrolytic Kinetics and Stability of Antimetastasis NAMI and NAMI-A Derivatives Containing 4-Ethyl Pyridine
在线阅读 下载PDF
导出
摘要 制备了trans-[RuCl4(DMSO)(4-EtPy)]Na·2DMSO(4-EtPy=4-乙基吡啶)(化合物1)和trans-[RuCl4(DMSO)(4-EtPy)][(4-EtPy)H](化合物2)。用UV、NMR研究了化合物在pH 7.40及5.00(0.15 mol·L-1NaCl,37℃)缓冲液中的水解机理-动力学和溶液稳定性。测得各水解反应表观速率常数、半衰期。研究结果表明:两个化合物的Ⅰ氯、Ⅱ氯及DMSO水解反应机理均与NAMI-A相似,但其各级水解速率比NAMI-A略快,即用4-EtPy取代咪唑环,可加快NAMI-A衍生物的Ⅰ氯、Ⅱ氯及DMSO水解反应速率。在含氮配体相同时,NAMI-A衍生物比相应NAMI衍生物的稳定性稍好。化合物在酸性溶液中的稳定性高于中性溶液。提供了用核磁法定量测定NAMI-A衍生物的水解机理-动力学。 trans-[RuC14(DMSO)(4-EtPy)]Na .2DMSO (4-EtPy=4-Ethyl pyridine) (compound 1) and trans[RuC14 (DMSO)(4-EtPy)][(4-EtPy)H] (compound 2) were synthesized. Their hydrolytic mechanismkinetics in pH 7.40/ 5.00 buffer solution and solution stabilities were studied by UV and NMR spectroscopy. Observed rate constant (kobs) and half-life time (t1/2) of the compounds were measured and calculated respectively. The result shows that the 1st and 2nd chloro-hydrolysis as well as DMSO-hydrolysis mechanisms for two compounds are very similar to that for NAMI-A. However, the measured hydrolytic rates of two compounds are somewhat faster than that of related NAMI-A, which means that replacing imidazole ring by 4-EtPy containing electron donating group would accelerate hydrolytic rate of NAMI-A derivatives. With the same nitrogen-donor ligand, NAMI-A derivative seems a little bit more stable than related NAMI derivative. The NMR method to quantitatively determine the mechanism-kinetics of NAMI-A derivatives was also provided.
出处 《无机化学学报》 SCIE CAS CSCD 北大核心 2012年第10期2049-2058,共10页 Chinese Journal of Inorganic Chemistry
基金 澳门科技发展基金(No.012/2009/A1) 中国中医科学院基本科研业务费自主选题(No.ZZ03064,Z02089)资助项目
关键词 钌化合物 4-乙基吡啶 水解动力学 稳定性 核磁法 ruthenium complexes 4-ethyl pyridine hydrolytic kinetics stabilities NMR
作者简介 通讯联系人:梁国刚。E-mail:Lguogang200@126.com
  • 相关文献

参考文献35

  • 1Sava G, Clerici K, Capozzi I, et al. Anticancer Drugs, 1999, 10(1):129-138.
  • 2Sara G, Gagliardi R, Bergamo A, et al. Anticartcer Res., 1999, 19(2A):969-972.
  • 3Bergamo A, Gava B, Alessio E, et al. Int. J. Oncol., 2002,21 (6):1331-1338.
  • 4Sava G, Bergamo A, Zorzet S, et al. Eur. J. Cancer., 2002, 38(3):427-435.
  • 5Bacac M, Hotze A C, van der Schilden K, et al. J. Inorg. Biochem., 2004,98(2):402-412.
  • 6Khalaila I, Bergamo A, Bussy F, et al. Int.J. OncoL, 2006,29(1):261-268.
  • 7Rademaker-Lakhai J M, van den Bongard D, Pluim D, et al. Clin. Cancer Res., 2004,10(11):3717-3727.
  • 8Casini A, Mastrobuoni G, Terenghi M, et al. J. BioL lnorg. Chem., 2007,12(8):1107-1117.
  • 9Groessl M, Tsybin Y O, Hartinger C G, et al. J. BioL Inorg. Chem., 2010,15(4):677-688.
  • 10LIANGYao-Hua(梁曜华),LIANGGuo.Gang(梁国刚).Chinese J. Inorg. Chem.(Wuji Huaxue Xuebao), 2008,24(12): 1983-1988.

二级参考文献26

  • 1Alessio E. , Mestroni G. , Bergamo A. , Sara G.. Curr. Top Med. Chem. [J] , 2004, 4(15) : 1525--1535.
  • 2Chen J. ,Chen L. , Liao S. , Zheng K. , Ji L.. J. Phys. Chem. B[J] , 2007, 111(27) : 7862--2769.
  • 3Bouma M. , Nuijen B. , Jansen M. T. , Sara G. , Flaibani A. , Bult A. , Beijnen J. H.. Int. J. Pharm.[J].2002, 248(1/2) : 239-- 246.
  • 4Bouma M. , Nuijen B. , Jansen M. T. , Sara G. , Bult A. , Beijnen J. H.. J. Pharm. Biomed. Anal. [J] , 2002, 30(4) : 1287--1296.
  • 5Besker N. , Coletti C. , Marrone A. , Re N.. J. Phys. Chem. B[J] , 2008, 112(13) : 3871--3875.
  • 6Frausin F. , Scarcia V. , Cocchietto M. , Furlani A. , Serli B. , Alessio E. , Sava G.. J. Pharmacol. Exp. Ther. [J], 2005, 313(1 ) :227--233.
  • 7Delferro M. , Marchio L. , Tegoni M. , Tardito S. , Franchi-Gazzola R. , Lanfranchi M.. Dalton Trans. [ J] , 2009, (19) : 3766--3773.
  • 8Ravera M. , Baracco S. , Cassino C. , Zanello P. , Osella D.. Dalton Trans. [J] , 2004,(15) : 2347--2351.
  • 9LIANGYao-Hua(梁曜华) LIANGGuo-Gang(梁国刚).澳门科技大学学报,2008,2(1):36-42.
  • 10Alessio E. , Balducci G. , Calligaris M. , Costa G. , Attia W. M. , Mestroni G., Inorg. Chem. [J], 1991,30(4) : 609--618.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部